Skip to main content
. 2020 Jun 27;21(13):4579. doi: 10.3390/ijms21134579
ADC Antibody Drug Coniugated
BC Breast Cancer
BL1/2 Basal-Like 1/2
BRCA1/2 BReast CAncer type 1 and Type 2
CSCs Cancer Stem Cells
CTCs Circulating Tumor Cells
dMMR Mismatch Repair deficiency
DSBs DNA Double Strand Breaks
DCs Dendritic Cells
DFS Disease Free Survival
EMT Epithelial Mesenchymal Transition
ER Estrogen Receptor
FDA Food and Drug Administration
FFPE Formalin-fixed paraffin embedded
GEP Gene Expression Profile
gBRCAm germline BRCA mutations
GPNMB Glycoprotein non-metastatic b
HBOC Hereditary Breast and Ovarian Cancer Syndrome
HRD Homologous Recombination Deficiency
HRD-LOD HRD-Loss of Heterozygosity
HRD-LST HDR-Large Scale Transition
HRD-TAI HDR-Telomeric Allelic Imbalance
HER2 Human Epidermal Growth Factor Receptor 2
HR Homologous Recombination
HRR Homologous Recombination Repair
IC Immune Cells
ICI Immune Checkpoint Inhibitor
IM Immunomodulatory
LAG3 Lymphocyte-associated gene 3
LAR Luminal Androgen Receptor
MAP Mitogen-Activated Protein
MBC Metastatic Breast Cancer
MHC Major Histocompatibility Complex
MMAE Microtubule-disrupting agent monomethyl auristatin E
MMR Mismatch Repair
MSI Microsatellite Instability
MSI-H High Microsatellite Instability
MSL Mesenchymal Stem-Like
mTOR Mammalian Target Of Rapamycin
mTORC1 mTOR complex 1
NGS Next Generation Sequencing
NHEJ Non-Homologous End Joining
NK Natural Killer
ORR Objective Response Rate
OS Overall Survival
OXPHOS Oxidative Phosphorylation
pCR Pathological Complete Response
PARP Poly ADP-ribose polymerase
PARPi Poly ADP-ribose polymerase Inhibitors
PD-1 Programmed Cell Death-1
PD-L1 Programmed Cell Death Ligand-1
PDX Patient-Derived-Xenograft
PFS Progression Free Survival
PI3K Phosphatidylinositol 3-kinase
PIK3CA Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit, alpha
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate
PTEN Phosphatase and Tensin Homolog
PR Progesterone Receptor
RCB Residual Cancer Burden
sBRCAm Somatic BRCA mutations
TC Tumor Cells
TIL Tumor Infiltrating Lymphocytes
TMB Tumor Mutational Burden
TNBC Triple Negative Breast Cancer
UNS Unstable